4
Changes in Ownership
Kiniksa Pharmaceuticals International, plc Filed Acc 0001415889-24-028431
CHIEF FINANCIAL OFFICER sold 15,116 shares at an average $21.37 ($323,009)
- CHIEF FINANCIAL OFFICER acquired 15,116 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-03 | Option exercise 10b5-1 | +8,969 | $10.76 | $96,506 | 31,927 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-03 | Sale 10b5-1 | −8,969 | $21.45 | $192,385 | 22,958 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-04 | Option exercise 10b5-1 | +5,024 | $10.76 | $54,058 | 27,982 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-04 | Sale 10b5-1 | −5,024 | $21.25 | $106,760 | 22,958 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-05 | Option exercise 10b5-1 | +1,123 | $10.76 | $12,083 | 24,081 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-05 | Sale 10b5-1 | −1,123 | $21.25 | $23,864 | 22,958 | D |
| Derivatives | |||||||
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-03 | Option exercise · Share Option 10b5-1 | −8,969 | 33,081 | D | ||
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-04 | Option exercise · Share Option 10b5-1 | −5,024 | 28,057 | D | ||
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-05 | Option exercise · Share Option 10b5-1 | −1,123 | 26,934 | D | ||
| Open-market sales · 15,116 sh · avg $21.37 · $323,009 | |||||||
Loading xslF345X05/form4-12062024_121225.xml…